What Verdica's 799 score means for AMGEN
AMGEN's composite score of 799 out of 850 places it in the "strong" performance band (740–799), indicating consistent regulatory compliance across the measured dimensions. This score reflects data aggregated from state pharmacy boards, FDA records, and DEA filings—the primary regulatory touchpoints for pharmaceutical manufacturers and distributors.
A score in this band suggests that AMGEN meets or exceeds baseline compliance requirements across most areas tracked by regulators. However, it is not in the "excellent" tier (800–850), meaning there are identifiable gaps or areas where performance falls short of the highest standard. For a business owner or consumer evaluating AMGEN as a pharmacy provider, this score signals a trustworthy entity with a solid compliance track record, but one that warrants routine due diligence before engagement.
The lack of independent customer reviews indexed on Verdica means this assessment is based purely on regulatory data, not user experience. That data source limitation is important context: the score reflects what regulators can measure, not operational quality, customer service, or real-world outcomes reported by other pharmacies or patients.
How the sub-scores break down
Product Approval (850/850): This perfect score indicates that AMGEN's pharmaceutical products meet FDA approval standards across the board. In the pharmacy industry, this dimension tracks whether drugs are legally marketed, properly labeled, and cleared through FDA channels. A score of 850 means no flagged products, unapproved claims, or regulatory holds tied to product authorization.
Manufacturer Profile (720/850): This sub-score reflects AMGEN's operational and licensing status as tracked by state boards of pharmacy and related regulators. A score of 720 is notably lower than the product approval score, suggesting some gaps in manufacturing oversight, facility compliance, or licensing completeness. This could indicate historical issues resolved, ongoing minor deficiencies, or variance in how different regulatory jurisdictions rate the entity. It is the weakest of the three sub-scores and represents the most material compliance risk area.
FDA Compliance (830/850): This reflects AMGEN's adherence to FDA regulations governing manufacturing, quality assurance, adverse event reporting, and facility inspections. A score of 830 indicates strong compliance but is not perfect. Regulators may have documented minor observations during inspections, inspection follow-ups, or compliance correspondence that prevented a higher score. This is a common profile for large manufacturers that operate at scale.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensing records and disciplinary histories for manufacturers and distributors. They track facility approvals, renewal compliance, and any actions taken against the entity—such as warnings, license restrictions, or revocations. These records directly feed into the Manufacturer Profile score.
The FDA monitors pharmaceutical manufacturers through inspections, testing of product samples, and review of manufacturing records. Regulators look for deviations from Current Good Manufacturing Practices (CGMP), unresolved quality issues, or failure to report adverse events. Minor inspection observations typically don't result in enforcement action but do lower compliance scores. Major issues—contamination, fraudulent data, repeated failures to correct deficiencies—trigger Warning Letters, consent decrees, or seizures.
The DEA tracks controlled substance manufacturing, inventory control, and diversion prevention for applicable products. For manufacturers producing scheduled pharmaceuticals, any discrepancies in records, theft, or loss can trigger investigation and score reduction.
These three data streams collectively indicate whether an entity operates within the boundaries of federal and state pharmaceutical law. They do not measure customer satisfaction, speed of delivery, or pricing competitiveness.
Bottom line
AMGEN's 799 score reflects a strong regulatory compliance profile with no critical deficiencies. Before engaging, cross-check the current FDA facility inspection history and any open compliance correspondence—particularly given the slightly lower Manufacturer Profile sub-score—to understand whether observed gaps have been addressed or remain active.